FBFabian J. Brunner

Fabian J. Brunner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fabian J. Brunner has a total of 159 co-authors. Here are the top co-authors by number of shared publications:

  • Christoph Waldeyer

    Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center of Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lübeck, Hamburg, Germany

    8 shared publications
  • Moritz Seiffert

    Department of Cardiology and Angiology (Medical Clinic II), University Hospital Bergmannsheil, Ruhr University Bochum , Bürkle-de-la-Camp-Platz 1, Bochum 44789

    8 shared publications
  • Stefan Blankenberg

    7 shared publications
  • Stefan Blankenberg

    Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    7 shared publications
  • Alina Goßling

    Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg , Hamburg

    5 shared publications
  • Benjamin Bay

    Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf

    4 shared publications

Latest Publications

  • Open Access

    Incident coronary heart disease, residual risk and traditional cardiovascular risk factors in the community: The role of the lipid-inflammatory axis

    by Natalie Arnold, Christina Magnussen, Jessica Weimann, Alina Goßling, Fabian J. Brunner, Marco M. Ferrario, Paolo Brambilla, Giancarlo Cesana, Valerio Leoni, Luigi Palmieri, et al.

  • Top Cited Papers

    The cTnI/cTnT Ratio in Myocardial Injury

    by Tobias Zimmermann, Luca Koechlin, Joan Walter, Dorien M. Kimenai, Anda Bularga, Giulia Milan, Antonio Sileo, Deborah Fusco, Xiya Mu, Fabian J. Brunner, et al.


  • Open Access

    Manual support during robotic-assisted percutaneous coronary intervention

    by Benjamin Bay, Alina Goßling, Jonathan Rilinger, Constantin von Zur Mühlen, Felix Hofmann, Holger Nef, Helge Möllmann, Caroline Kellner, Moritz Seiffert, Fabian J. Brunner

    Background: Robotic-assisted percutaneous coronary intervention (R-PCI) is an efficacious and safe treatment option for coronary artery disease. However, predictors of manual support during R-PCI are unknown, which we aimed to investigate in a multi-center study. Methods: We utilized patient-level data from R-PCIs carried out from 2020 to 2022 at four sites in Germany. Manual support was defined as the combination of partial manual assistance, where the procedure is ultimately completed using robotic techniques, and manual conversion. A two-step selection process based on akaike information criteria was used to identify the ideal multivariable model predicting manual support. Results: In 210 patients (median age 69.0 years; 25.7% female), a total of 231 coronary lesions were treated by R-PCI. Manual support was needed in 46 lesions (19.9%). Procedures requiring manual support were associated with significantly longer procedural times, greater total contrast fluid volumes, longer fluoroscopy times, and higher dose-area products. Amongst the predictors of manual support were lesions in the left anterior descending artery [OR: 1.09 (95%-CI: 0.99–1.20)], aorto-ostial lesions [OR: 1.35 (95%-CI: 1.11–1.64)], chronic total occlusions [OR: 1.78 (95%-CI: 1.38–2.31)], true bifurcations [OR: 1.37 (95%-CI: 1.17–1.59)], and severe calcification [OR: 1.13 (95%-CI: 1.00–1.27)]. Conclusion: Our findings reveal that nearly one out five of patients undergoing R-PCI required manual support, which was linked to longer procedure durations. Predictors of manual support reflected characteristics of more complex coronary lesions. These results highlight the limitations of current R-PCI platforms and underscore the need for technical advancements to address different clinical scenarios. Graphical Predictors for manual support during robotic-assisted percutaneous coronary intervention. 95%-CI: 95%-confidence interval, DES: Drug eluting stent, OR: Odds ratio, LAD: Left anterior descending coronary artery, R-PCI: robotic-assisted percutaneous coronary intervention.


  • Percutaneous Coronary Interventions Using Calcium Modification and Intravascular Imaging

    by Fabian J. Brunner, Peter Moritz Becher, Marko Remmel, Jessica Weimann, Benjamin Bay, Christoph Waldeyer, Benedikt Schrage, Stefan Blankenberg, Peter Clemmensen, Moritz Seiffert


  • Impact of Lipoprotein(a) Level on Low-Density Lipoprotein Cholesterol– or Apolipoprotein B–Related Risk of Coronary Heart Disease

    by Natalie Arnold, Christopher Blaum, Alina Goßling, Fabian J. Brunner, Benjamin Bay, Tanja Zeller, Marco M. Ferrario, Paolo Brambilla, Giancarlo Cesana, Valerio Leoni, et al.


  • Procedural and one-year outcomes of robotic-assisted versus manual percutaneous coronary intervention

    by Benjamin Bay, Luisa M. Kiwus, Alina Goßling, Lukas Koester, Christopher Blaum, Benedikt Schrage, Peter Clemmensen, Stefan Blankenberg, Christoph Waldeyer, Moritz Seiffert, et al.

    The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)


  • Open Access

    Temporal trends, patient characteristics and hospital volume outcomes after alcohol septal ablation and septal myectomy for treatment of obstructive hypertrophic cardiomyopathy

    by P M Becher, J Weimann, F Brunner, E Zengin-Sahm, M Remmel, B Schrage, M Patten, C Detter, H Reichenspurner, P Kirchhof, et al.

    Background: Hypertrophic obstructive cardiomyopathy (HOCM) represents a clinically and morphologically diverse hereditary cardiac disease that is frequently associated with poor prognosis. Nationwide data on septal reduction therapy (SRT), alcohol septal ablation (ASA) and septal myectomy (SM), remains scarce. The aim of this study was to investigate (i) temporal trends, (ii) patient characteristics, (iii) in-hospital outcomes, and associations between institutional procedural volumes and outcomes after ASA and SM in a large-scale nationwide cohort. Methods: Using data from the German Federal Bureau of Statistics, this study analyzed all patients with HOCM who were hospitalized for ASA or SM in a nationwide inpatient database in Germany between January 1, 2006, through December 31, 2019. Rates of adverse in-hospital events (in-hospital mortality, need for permanent pacemaker) were examined. Multivariate logistic regression analysis was performed to compare overall outcomes after each procedure based on tertiles of hospital volumes of ASA and SM. Results: A total of 8,514 patients underwent SRT, of whom 5,293 (62.2%) underwent ASA and 3,221 (37.8%) SM. Annual numbers for SM and ASA steadily increased over time: ASA procedures increased from 329 in 2006 to 451 in 2019 and SM procedures increased from 191 in 2006 to 222 in 2019, respectively. Patients with SM were older (mean 67.4 vs. 60.2 years), less likely female (56.4% vs. 49.9%), and had a higher burden of comorbidities (e.g., diabetes, atrial fibrillation, heart failure, chronic kidney disease) compared to patients with ASA. Over an observational period of 14 years, the majority of both ASA and SM procedures were performed at hospitals in the lowest volume category (≤20 procedures). The overall in-hospital mortality was higher in patients with SM (6.8%) compared to patients with ASA (0.8%), whereas the need for pacemaker implantation was more often observed in patients with ASA (19.3% vs. 13.1%; p<0.001). The lowest tertile of SM volume among hospitals was independently associated with an increased risk of in-hospital mortality (adjusted odds ratio (lowest vs. highest tertile), 2.64; 95% confidence interval, 1.49-4.66), whereas being in the lowest vs. the highest tertile of ASA by volume was not independently associated with risk of in-hospital mortality and adverse events. Conclusion: In this contemporary cohort with more than 8,500 cases of SRT between 2006 and 2019, the majority of SRT was performed at centers with a low volume of SM and ASA procedures. Low SM volume was independently associated with increased in-hospital mortality, whereas low ASA volume was not associated with adverse outcomes. Our findings may help to further understand how institutional SRT procedural volumes affects outcomes and might encourage referral of patients with HOCM to centers of excellence for SRT.


  • Open Access

    Association of inflammation with shock severity, 30-day mortality and therapy response in patients with cardiogenic shock

    by A Dettling, J Weimann, J Sundermeyer, B Beer, L Besch, P Becher, F Brunner, S Kluge, P Kirchhof, S Blankenberg, et al.

    Background: Elevated concentrations of C-reactive protein (CRP) and other circulating cytokines are often found in cardiogenic shock (CS). The role of systemic inflammation in the pathogenesis of cardiogenic shock remains unclear. To address this, associations between elevated plasma CRP concentrations upon admission with shock severity, 30-day mortality, and therapy response were analysed in patients with CS. Methods: Plasma CRP concentrations were identified in a large data base containing unselected patients admitted with cardiogenic shock. The association between plasma CRP concentrations and CS severity (SCAI stage, reference SCAI B) was analyzed using adjusted linear and logistic regression models. The association between plasma CRP concentrations and 30-day mortality was analyzed using adjusted Cox regression models. The interaction between plasma CRP concentrations and treatment response was assessed by fitting an interaction term between plasma CRP concentrations and the use of mechanical circulatory support (MCS) in the above described Cox regression models. Results: A total of 1116 patients were analysed. Median age was 70 years [interquartile range 58-78.6 years], 71.3% were male, 47.7% presented with CS due to acute myocardial infarction, and 58.3% with prior cardiac arrest. The median plasma CRP concentration was 17 mg/dl [interquartile range 5.0-71.0 mg/dl]. Plasma CRP concentrations were equally distributed among patients with higher vs. lower shock severity (higher SCAI stage). After adjustment for CS severity and other cofounders, higher plasma CRP concentrations were associated with higher 30-day mortality [8% relative risk increase per 50 mg/dl increase in plasma CRP, range 3-13%, adjusted pmedian: MCS use 0.92 (95%-CI: 0.67-1.26; p=0.59)], while plasma CRP concentration was associated with 30-day mortality in patients not treated with MCS [HR for CRP>median 1.50 (95%-CI: 1.21-1.86; p<0.001); p-interaction=0.01]. Conclusion: Increased concentrations of inflammatory cytokines are associated with a higher 30-day mortality regardless of shock severity. This association is abolished when mechanical circulatory support systems are used, potentially by providing sufficient end-organ perfusion. This interaction calls for further research on this topic.

  • Open Access

    Association of High‐Sensitivity Troponin T and I Blood Concentrations With All‐Cause Mortality and Cardiovascular Outcome in Stable Patients—Results From the INTERCATH Cohort

    by Benjamin Bay, Alina Goßling, Christopher M. Blaum, Friederike Kroeger, Luise Koppe, Thiess Lorenz, Lukas Koester, Peter Clemmensen, Dirk Westermann, Paulus Kirchhof, et al.

    Background: The association between high‐sensitivity troponin T (hsTnT) and high‐sensitivity troponin I (hsTnI) and outcome when adjusted for confounders including the angiographical severity of coronary artery disease (CAD) remains largely unknown. We therefore aimed to explore whether hsTnT and hsTnI blood levels increase with CAD severity and add independent predictive information for future major adverse cardiovascular events and all‐cause mortality in stable patients. Methods and Results: Patients from the INTERCATH cohort with available coronary angiography and hsTnT and hsTnI concentrations were included. Troponin concentrations were quantified via hsTnT (Roche Elecsys) and hsTnI (Abbott ARCHITECT STAT). To investigate the association of hsTnT and hsTnI with outcome, a multivariable analysis adjusting for classical cardiovascular risk factors, low‐density lipoprotein cholesterol, estimated glomerular filtration rate, hs‐CRP (high‐sensitivity C‐reactive protein), NT‐proBNP (N‐terminal pro–brain natriuretic peptide), and Gensini score was carried out. Of 1829 patients, 27.9% were women, and the mean age was 68.6±10.9 years. Troponin blood concentrations were higher in patients with diagnosed CAD compared with those without. Using a linear regression model current smoking, arterial hypertension, estimated glomerular filtration rate, hs‐CRP, NT‐proBNP, and CAD severity as graded by the Gensini and SYNTAX scores were associated with high‐sensitivity troponin levels. Patients were followed for 4.4 years (25th and 75th percentiles: 4.3, 4.4). After multivariable adjustment, all‐cause mortality was predicted by hsTnT (hazard ratio [HR], 1.7 [95% CI, 1.5–2.2], P P P =0.032) remained as an independent predictor of major adverse cardiovascular events after adjusting for most possible confounders, including CAD severity (hsTnT: HR, 1.0 [95% CI, 0.9–1.2], P =0.95). Conclusions: After adjusting for classical cardiovascular risk factors, low‐density lipoprotein cholesterol, estimated glomerular filtration rate, hs‐CRP, NT‐proBNP, and CAD severity, hsTnT and hsTnI were independently associated with all‐cause mortality, but only hsTnI was associated with major adverse cardiovascular events in stable patients undergoing coronary angiography. Registration: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT04936438.